亚胺培南/西司他丁治疗院内获得性重症肺炎的疗效观察  

Efficacy of Imipenem/Cilastatin in Severe Hospital-Acquired Pneumonia

作　　者：谭世繁[1] 罗宁[1] 宋一波[1] 陈春杰[1] 陈智华[1] 黄壮志[1] 

机构地区：[1]广东省茂名市人民医院呼吸内科,525000

出　　处：《中华全科医学》2011年第7期1055-1056,共2页Chinese Journal of General Practice

摘　　要：目的研究亚胺培南/西司他丁治疗院内获得性重症肺炎的疗效及安全性,为临床经验性用药提供参考。方法亚胺培南/西司他丁治疗院内获得性重症肺炎共93例,剂量为亚胺培南/西司他丁0.5-1.0 g静脉滴注,每8 h或12 h一次,疗程7-10 d。观察临床症状及不良反应,并对患者的痰液进行培养及药敏试验。结果亚胺培南/西司他丁治疗院内获得性重症肺炎的临床有效率为78.4%（73/93）,细菌清除率为89.1%（74/83）,不良反应率为5.3%（5/93）。结论亚胺培南/西司他丁治疗院内获得性重症肺炎的疗效确切、安全性好,但应密切监测细菌耐药性的变化,根据病原学及临床效果及时调整治疗方案。Objective To investigate the clinical effect and safety of Imipenem/Cilastatin on severe hospital-acquired pneumonia（HAP）.Methods A total of 93 patients with severe HAP were treated with Imipenem/Cilastatin[0.5-1.0 g,intravenously guttae,q8h or q12h×（7-10 d）].The clinical efficacy and adverse reactions were recorded.The bacteria from sputum were cultured;the antibiotic sensitivity tests were performed.Results The clinical effective rate of Imipenem/Cilastatin for HAP was 78.4%（73/93）,the bacterial elimination rate was 89.1%（74/83）,and the adverse reaction rate was 5.3%（5/93）.Conclusion Imipenem/Cilastatin is effective and safe on severe HAP.According to the changes of bacterial resistance to antibiotics,etiology and clinical effects,the therapeutic scheme should be optimized.

关 键 词：亚胺培南 西司他丁 院内获得性重症肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]